Filtered By:
Drug: Simvastatin
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 142 results found since Jan 2013.
Progressive proximal muscle weakness with subacute onset in an elderly patient: a case report
CONCLUSION: In this case, exclusion of inflammatory myopathies, metabolic muscle disorders and other neurological diseases is necessary for establishing a reliable diagnosis. In SINAM, simply discontinuing statin is often insufficient and aggressive immunosuppression or immunomodulation therapy is needed to achieve disease remission. This case aims to demonstrate that statins can induce serious muscular diseases that require aggressive immunosuppression.PMID:36544374 | DOI:10.33588/rn.7601.2021276
Source: Revista de Neurologia - December 22, 2022 Category: Neurology Authors: A Martins G Nadais M Pinto R Taipa L Costa S Pimenta Source Type: research
Genvoya-Associated and Simvastatin-Associated Noninflammatory and Nonautoimmune Myopathy: A Case Report and Literature Review
In this study, we describe a case of biopsy-proven noninflammatory and nonautoimmune myopathy associated with the use of simvastatin and Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate) and review 3 previously reported similar cases. Our patient presented with acute proximal limb weakness and significantly elevated serum creatine kinase. Muscle biopsy revealed scattered degenerating and regenerating muscle fibers without evidence for an inflammatory process. She did not respond to empiric treatment with high-dose intravenous steroids and intravenous immunoglobulin. Her creatine kinase only beg...
Source: Journal of Clinical Neuromuscular Disease - November 24, 2022 Category: Neurology Tags: Case Reviews Source Type: research
A systematic review of the drug –drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies
AbstractColchicine and statins are frequently co-prescribed for prevention and treatment of cardiovascular diseases, auto-inflammatory diseases, and gout. Both are substrates and inhibitors of the cytochrome P-450 (CYP) 3A4 isozyme and P-glycoprotein so that taken together, they represent a clinically significant interaction. Data suggest the interaction may be associated with potentially life-threatening myopathies and rhabdomyolysis. The purposes of this systematic review (SR) were to gather and appraise evidence surrounding the statin-colchicine drug interaction and discuss related risk-mitigation strategies. An electro...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 27, 2022 Category: Drugs & Pharmacology Authors: Nicholas C. Schwier,
Cyrille K. Cornelio,
Paul M. Boylan Tags: REVIEW Source Type: research
A systematic review of the drug ‐drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies
AbstractColchicine and statins are frequently co-prescribed for prevention and treatment of cardiovascular diseases, auto-inflammatory diseases, and gout. Both are substrates and inhibitors of the cytochrome P-450 (CYP) 3A4 isozyme and P-glycoprotein so that taken together, they represent a clinically significant interaction. Data suggest the interaction may be associated with potentially life-threatening myopathies and rhabdomyolysis. The purposes of this systematic review (SR) were to gather and appraise evidence surrounding the statin-colchicine drug interaction and discuss related risk-mitigation strategies. An electro...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 18, 2022 Category: Drugs & Pharmacology Authors: Nicholas C. Schwier,
Cyrille K. Cornelio,
Paul M. Boylan Tags: REVIEW Source Type: research
The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms
Clin Pharmacol Ther. 2022 Feb 12. doi: 10.1002/cpt.2557. Online ahead of print.ABSTRACTStatins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed medications in the world. Statin-associated musculoskeletal symptoms (SAMS) impact statin adherence and ultimately can impede the long-term effectiveness of statin therapy. There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B1 encodes a transporter (SLCO1B1; alternative names include OATP1B1 or OATP-C) that facilitates the hepatic uptake of all statins. ABC...
Source: Clinical Pharmacology and Therapeutics - February 13, 2022 Category: Drugs & Pharmacology Authors: Rhonda M Cooper-DeHoff Mikko Niemi Laura B Ramsey Jasmine A Luzum E Katriina Tarkiainen Robert J Straka Li Gong Sony Tuteja Russell A Wilke Mia Wadelius Eric A Larson Dan M Roden Teri E Klein Sook Wah Yee Ronald M Krauss Richard M Turner Latha Palaniappan Source Type: research
Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & amp; genetics
CONCLUSIONS: The overall incidence of myopathy in patients taking statins was 27.8%. Myopathy was directly related to dose and type of statin used. The use of Fluvastatin XL 80 mg and Rosuvastatin 10 mg showed less incidence of myopathy compared with other statins.PMID:35145672 | PMC:PMC8818528 | DOI:10.1016/j.amsu.2022.103304
Source: Annals of Medicine - February 11, 2022 Category: Internal Medicine Authors: Waddah Abed Mousa Abujbara Anwar Batieha Kamel Ajlouni Source Type: research
Common Statin Intolerance Variants in ABCB1 and LILRB5 Show Synergistic Effects on Statin Response: An Observational Study Using Electronic Health Records
Conclusion: We report two genetic variants for statin adverse drug reactions (ADRs) that are associated with statin efficacy. While the ABCB1 variant has been shown to have an association with statin pharmacokinetics, no similar evidence for LILRB5 has been reported. These findings highlight the value of genetic testing to deliver precision therapeutics to statin users.
Source: Frontiers in Genetics - October 1, 2021 Category: Genetics & Stem Cells Source Type: research
mTORC2 is an important target for simvastatin-associated toxicity in C2C12 cells and mouse skeletal muscle - Roles of Rap1 geranylgeranylation and mitochondrial dysfunction
In conclusion, mTORC2 inhibition is an important mechanism of simvastatin-induced myotoxicity. Simvastatin inhibits mTORC2 by impairing geranylgeranylation of Rap1 and by inducing mitochondrial dysfunction.PMID:34461118 | DOI:10.1016/j.bcp.2021.114750
Source: Biochemical Pharmacology - August 30, 2021 Category: Drugs & Pharmacology Authors: Gerda M Sanvee Leonie Hitzfeld Jamal Bouitbir Stephan Kr ähenbühl Source Type: research
Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy
The objectives would be to prevent liver-related morbidity and mortality rather than treating cirrhosis complications to take additional information that makes it possible to add statins to the standard of care of these patients.PMID:34366626 | PMC:PMC8326251 | DOI:10.3748/wjg.v27.i28.4639
Source: World Journal of Gastroenterology : WJG - August 9, 2021 Category: Gastroenterology Authors: Alberto E Mu ñoz Florencia D Pollarsky M ónica Marino Mariano Cartier Horacio V ázquez Pablo Salgado Gustavo Romero Source Type: research
